764 related articles for article (PubMed ID: 28249894)
1. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
Feng X; Zhang L; Acharya C; An G; Wen K; Qiu L; Munshi NC; Tai YT; Anderson KC
Clin Cancer Res; 2017 Aug; 23(15):4290-4300. PubMed ID: 28249894
[No Abstract] [Full Text] [Related]
2. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Krejcik J; Casneuf T; Nijhof IS; Verbist B; Bald J; Plesner T; Syed K; Liu K; van de Donk NW; Weiss BM; Ahmadi T; Lokhorst HM; Mutis T; Sasser AK
Blood; 2016 Jul; 128(3):384-94. PubMed ID: 27222480
[TBL] [Abstract][Full Text] [Related]
3. Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Krejcik J; Frerichs KA; Nijhof IS; van Kessel B; van Velzen JF; Bloem AC; Broekmans MEC; Zweegman S; van Meerloo J; Musters RJP; Poddighe PJ; Groen RWJ; Chiu C; Plesner T; Lokhorst HM; Sasser AK; Mutis T; van de Donk NWCJ
Clin Cancer Res; 2017 Dec; 23(24):7498-7511. PubMed ID: 29025767
[No Abstract] [Full Text] [Related]
4. Neutralization of interleukin-10 or transforming growth factor-β decreases the percentages of CD4+ CD25+ Foxp3+ regulatory T cells in septic mice, thereby leading to an improved survival.
Hiraki S; Ono S; Tsujimoto H; Kinoshita M; Takahata R; Miyazaki H; Saitoh D; Hase K
Surgery; 2012 Feb; 151(2):313-22. PubMed ID: 21982068
[TBL] [Abstract][Full Text] [Related]
5. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.
Tai YT; Lin L; Xing L; Cho SF; Yu T; Acharya C; Wen K; Hsieh PA; Dulos J; van Elsas A; Munshi N; Richardson P; Anderson KC
Leukemia; 2019 Feb; 33(2):426-438. PubMed ID: 30135465
[TBL] [Abstract][Full Text] [Related]
6. The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
Moreno L; Perez C; Zabaleta A; Manrique I; Alignani D; Ajona D; Blanco L; Lasa M; Maiso P; Rodriguez I; Garate S; Jelinek T; Segura V; Moreno C; Merino J; Rodriguez-Otero P; Panizo C; Prosper F; San-Miguel JF; Paiva B
Clin Cancer Res; 2019 May; 25(10):3176-3187. PubMed ID: 30692097
[TBL] [Abstract][Full Text] [Related]
7. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
8. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
van de Donk NWCJ; Usmani SZ
Front Immunol; 2018; 9():2134. PubMed ID: 30294326
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
10. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
11. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
12. CD38 targeted treatment for multiple myeloma.
Jelínek T; Mihályová J; Hájek R
Vnitr Lek; 2018; 64(10):939-948. PubMed ID: 30590941
[TBL] [Abstract][Full Text] [Related]
13. The role of regulatory B cells (Bregs) in the Tregs-amplifying effect of Sirolimus.
Song J; Xiao L; Du G; Gao Y; Chen W; Yang S; Fan W; Shi B
Int Immunopharmacol; 2016 Sep; 38():90-6. PubMed ID: 27258186
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.
Hadjiaggelidou C; Mandala E; Terpos E; Yiannaki E; Markala D; Triantafyllou T; Papatheodorou A; Gkastari V; Verrou E; Papanikolaou A; Konstantinidou P; Katodritou E
Ann Hematol; 2019 Jun; 98(6):1457-1466. PubMed ID: 30895351
[TBL] [Abstract][Full Text] [Related]
15. Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro.
Frassanito MA; Ruggieri S; Desantis V; Di Marzo L; Leone P; Racanelli V; Fumarulo R; Dammacco F; Vacca A
Eur J Haematol; 2015 Jul; 95(1):65-74. PubMed ID: 25409753
[TBL] [Abstract][Full Text] [Related]
16. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses.
Manna A; Kellett T; Aulakh S; Lewis-Tuffin LJ; Dutta N; Knutson K; Chini E; Pinilla-Ibarz J; Lamanna N; Manochakian R; Malavasi F; Sher T; Chanan-Khan AA; Ailawadhi S; Paulus A
Blood Adv; 2020 May; 4(10):2143-2157. PubMed ID: 32421811
[TBL] [Abstract][Full Text] [Related]
18. Targeting NAD
Kennedy BE; Sadek M; Elnenaei MO; Reiman A; Gujar SA
Trends Cancer; 2020 Jan; 6(1):9-12. PubMed ID: 31952784
[TBL] [Abstract][Full Text] [Related]
19. Elevated T regulatory cells in long-term stable transplant tolerance in rhesus macaques induced by anti-CD3 immunotoxin and deoxyspergualin.
Asiedu CK; Goodwin KJ; Balgansuren G; Jenkins SM; Le Bas-Bernardet S; Jargal U; Neville DM; Thomas JM
J Immunol; 2005 Dec; 175(12):8060-8. PubMed ID: 16339543
[TBL] [Abstract][Full Text] [Related]
20. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
Zhu C; Song Z; Wang A; Srinivasan S; Yang G; Greco R; Theilhaber J; Shehu E; Wu L; Yang ZY; Passe-Coutrin W; Fournier A; Tai YT; Anderson KC; Wiederschain D; Bahjat K; Adrián FJ; Chiron M
Front Immunol; 2020; 11():1771. PubMed ID: 32922390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
